New trial
Expanded Access: Bezuclastinib with Sunitinib in Advanced GIST
- Trial ID
- NCT06948955 on ClinicalTrials.gov
- Cancer type
- Gastrointestinal Stromal Tumor (GIST)
- Published in
- New in Oncology - May 14, 2025
Cogent Biosciences, Inc. is offering investigational bezuclastinib in combination with sunitinib to patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have no comparable treatment alternatives; the regimen aims for comprehensive inhibition of primary and secondary KIT mutations.
More in sarcoma and GIST
-
Trial result · Oct 22, 2026 · NCT04514484
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort -
New trial · Oct 8, 2026 · NCT07781891
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT -
Trial result · Sep 10, 2026 · NCT03069469
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients -
New trial · Aug 13, 2026 · NCT07725380
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma. -
Trial result · Aug 6, 2026 · NCT05218499
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR